S&P 500 eases slightly from fresh record high after stronger economic growth
On Tuesday, Benchmark analysts maintained their Speculative Buy rating and $8.00 price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) stock, representing significant upside potential from the current price of $1.21. According to InvestingPro data, the stock has faced headwinds recently, declining 14.38% in the past week and 25.6% year-to-date. The firm’s stance comes after Anebulo Pharmaceuticals reported its financial outcomes for the second quarter of fiscal year 2025 and provided updates on its clinical programs.
Anebulo Pharmaceuticals is currently focused on the development of intravenous (IV) selonabant, a treatment for acute cannabis-induced toxic effects. The company highlighted a key meeting with the US Food and Drug Administration (FDA) in December 2024 to discuss the urgent treatment needs, especially in pediatric cases, and the future development plans for the drug.
For the quarter ending in December, Anebulo posted a net loss of $2.5 million, or ($0.09) per share. This figure includes research and development expenses amounting to $1.2 million and general and administrative costs of $1.4 million. This performance marks a slight improvement from the net loss of $2.7 million, or ($0.11) per share, recorded in the same quarter of the previous year.
Additionally, the company successfully completed a $15 million equity private placement during the second quarter. As of the end of December 2025, Anebulo reported having approximately $15 million in cash reserves. InvestingPro analysis reveals the company maintains a strong liquidity position with a current ratio of 17.52, indicating robust short-term financial stability. Subscribers to InvestingPro can access 6 additional key insights about ANEB’s financial health and market position.
The analysts at Benchmark expressed their continued support for Anebulo stock by reiterating their Speculative Buy rating. With a current market capitalization of $49.71 million, the stock trades at 3.32 times book value. The financial results and the strategic moves made by the company, including the private placement and the ongoing dialogue with the FDA, appear to underpin Benchmark’s outlook on the stock.
In other recent news, Anebulo Pharmaceuticals has secured a $15 million capital raise, which will support the company’s upcoming Phase I study for its lead product candidate, selonabant. This funding was achieved through a private placement involving the sale of 15.2 million shares, with participation from 22NW and Nantahala Capital. Anebulo has also entered into a lock-up agreement with 22NW Fund, LP, following a private placement that resulted in a change of control. This agreement aims to address a compliance issue with Nasdaq, which had notified the company of a failure to meet listing rules. To resolve this, Anebulo plans to seek stockholder approval to lift voting and transfer restrictions at its annual meeting scheduled for April 4, 2025. The company has until April 10, 2025, to comply with Nasdaq’s requirements. Additionally, Anebulo has revised its Loan and Security Agreement, reducing its borrowing limit to approximately $3 million. These developments reflect Anebulo’s ongoing efforts to strengthen its financial position and regulatory compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.